Rose Ventures

What Rose Ventures does

Rose Ventures Inc. is a privately held life science venture and advisory firm founded in 2021 and led by Dr. Stan Rose, a serial genomics entrepreneur with more than three decades of operating experience. The firm works with early-stage companies developing innovative, high-impact life science products and services, providing financing, strategic advisory, and access to a network of life scientists, entrepreneurs, and contacts spanning industry, academia, finance, and government. Historically, the firm has backed companies across genomics tools, molecular diagnostics, pluripotent stem cells, protein immunoassays, transplant diagnostics, and biotech commercialization, with several prior portfolio companies acquired by Roche (NimbleGen, 2007), Affymetrix (Genetic MicroSystems, 2000), Bio-Techne (CyVek, 2014), FujiFilm (Cellular Dynamics, 2015), and Eurofins (Transplant Genomics, 2019).

As announced in January 2026, Rose Ventures became part of Miles Pond Press, LLC, stated it is fully allocated, and discontinued new fundraising or investing. The firm now operates solely as a boutique advisory practice offering strategic advisory services to a select group of clients. The current operating footprint consists of 1–10 employees headquartered in Falmouth, Massachusetts, with no public revenue or pricing disclosure. Marketing reach is driven by the firm website, an active blog, email newsletter, and Dr. Rose's published memoir "Can't Tame a Mongoose," which has won multiple 2024 book awards. The firm's competitive positioning rests on Dr. Rose's individual track record (more than $100M raised, more than $1B in shareholder value created) rather than scalable platform technology.

Name

Rose Ventures

Legal name

Rose Ventures Inc.

Website

https://roseventures.net

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Rose Ventures is a privately held life science venture and advisory firm led by Dr. Stan Rose, supporting early-stage companies developing innovative life science products; as of January 2026, it is fully allocated and operates only as a select-client advisory practice under Miles Pond Press, LLC.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital & Advisory

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Management Consulting Services (54161), Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro primary industry

Impact / ESG Venture Capital (FSANAAAG)

akta.pro secondary industry

Venture Capital Fundraising Placement (FSAEALAC)

Keywords

• Venture capital services
• Life science investing
• Strategic advisory services
• Biotech startup funding
• Early-stage investment

Headquarters

HQ city

Michigan

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Investment Returns: Rose Ventures generates returns through equity investments in early-stage life science companies. The firm was fully allocated as of January 2026 with no plans for future fundraising or investing.
2. Strategic Advisory Services: The firm continues to offer strategic advisory services for select clients, providing consulting on business strategy, commercialization, and operational expertise in the life sciences sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Rose Ventures is a life science venture firm that works with early-stage companies developing innovative, high-impact products and services. The firm provides strategic advisory services, leveraging operational expertise, industry connections, and a network spanning academia, finance, and government to help portfolio companies execute business plans and create value. As of January 2026, the firm is fully allocated with no plans for future fundraising or investing, and continues to offer strategic advisory services for select clients only.

Product overview

Rose Ventures is a life science venture firm that works with early-stage companies developing innovative, high-impact life science products and services. The firm offers strategic advisory services as its primary offering, providing portfolio companies and clients with access to operational expertise, industry networks, and guidance for executing business plans and creating stakeholder value. The firm is currently fully allocated with no plans for future fundraising or investing but continues to offer strategic advisory services for select clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic Advisory Services Rose Ventures offers strategic advisory services for select clients, providing operational expertise, industry connections, and guidance to early-stage life science companies developing innovative products and services. The engagement leverages the firm's network of life scientists, entrepreneurs, and contacts across academia, finance, and government to help clients execute business plans and create stakeholder value.

Quantifiable outcome

• More than $100 million raised in start-up funding
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Miles Pond Press, LLCcoreOthersAs of January 2026, Rose Ventures is now part of Miles Pond Press, LLC. The firm remains fully allocated with no plans for future fundraising or investing but continues to offer strategic advisory services for select clients.
• Council on Strategic RiskscoreStrategic or Co-development PartnerDr. Stan Rose serves as a senior fellow with the Council on Strategic Risks, participating in the Alliance to End Biological Threats.
• Next View PartnersminorStrategic or Co-development PartnerDr. Stan Rose serves as an advisor to Next View Partners, a venture fund dedicated to enhancing global water security by investing in innovative companies offering sustainable solutions.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Emerging players

• Mission BioCapital: Mission BioCapital is an early-stage life sciences venture firm that builds biotech companies, with a similar operator-driven model to Rose Ventures but at a smaller, more nascent scale.
• Cure Ventures: Cure Ventures is an early-stage life sciences venture firm focused on building new biotech companies, operating in the same niche as Rose Ventures but with a more recently established fund.

Direct peers

• ARCH Venture Partners: ARCH Venture Partners invests in early-stage life science and technology companies, comparable to Rose Ventures in its focus on founding and building breakthrough life science and biotech companies.
• 5AM Ventures: 5AM Ventures is a life sciences-focused venture capital firm investing in early-stage companies across therapeutics, diagnostics, and research tools, directly comparable to Rose Ventures' investment scope.
• Foresite Capital: Foresite Capital is a healthcare and life sciences-focused venture firm investing across stages, comparable to Rose Ventures in its thematic focus on genomics, diagnostics, and therapeutics.
• Avalon Ventures: Avalon Ventures is an early-stage venture firm with a portfolio that includes life science companies, comparable to Rose Ventures in its hands-on, founder-led approach to early-stage science investing.
• Atlas Venture: Atlas Venture is an early-stage venture capital firm focused on building biotech companies, with a portfolio approach that closely mirrors Rose Ventures' life science focus and early-stage investment style.
• Third Rock Ventures: Third Rock Ventures is a healthcare-focused venture firm that builds and launches companies around transformative science, comparable to Rose Ventures in life science stage and hands-on operational involvement.

Broad incumbents

• Lux Capital: Lux Capital invests in emerging science and technology ventures including life sciences, comparable to Rose Ventures through its early-stage biotech and genomics investments.
• Flagship Pioneering: Flagship Pioneering is a large, established life science innovation platform that creates and funds biotech companies; a much broader incumbent but operating in the same early-stage life science venture space as Rose Ventures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rose Ventures